Ultragenyx Q3 revenue $160M (+15% YoY); sells 25% Crysvita royalty for $400M

Ultragenyx Pharmaceutical Inc.

2025-Q3 EPS reported -$4.55 revenue$465,721,000

Total revenue $160M (+15% YoY); Crysvita $112M, Dojolvi $24M, Evkeeza $17M.
Net loss $180M ($1.81/share) vs $134M ($1.40) in Q3 2024; operating expense $331M.
Received $400M from OMERS for additional 25% Crysvita royalty; repurchase option at $540M.
FY2025 guidance reaffirmed: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M.
UX143 OI Phase 3 data expected year-end; DTX401 BLA submission on track for Q4 2025; UX111 BLA resubmission early 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.